Colorectal cancer is one of the most commonly diagnosed malignancies worldwide.

The development of colorectal cancer is a multistep process involving progressive molecular alterations in normal intestinal epithelial cells.

These alterations disrupt mechanisms responsible for cell proliferation, differentiation, DNA repair, apoptosis, and tissue organization.

Both genetic and epigenetic mechanisms contribute to this process.

Genetic alterations involve changes in the DNA sequence, including point mutations, insertions, deletions, chromosomal rearrangements, and copy-number abnormalities.

Epigenetic alterations, in contrast, influence gene activity without changing the underlying nucleotide sequence.

The interaction between these two mechanisms is particularly important in colorectal carcinogenesis.

Some colorectal tumors develop predominantly through chromosomal instability, whereas others demonstrate microsatellite instability or widespread promoter methylation.

These molecular pathways are not completely independent and can interact during tumor progression.

Understanding the molecular basis of colorectal cancer has contributed significantly to the development of molecular classification systems and targeted therapeutic strategies.

Molecular Pathways of Colorectal Carcinogenesis

Three major molecular pathways are frequently associated with colorectal cancer development:

• Chromosomal instability;
• Microsatellite instability; and
• CpG island methylator phenotype.

The chromosomal instability pathway is characterized by chromosomal gains and losses, aneuploidy, and mutations affecting important oncogenes and tumor-suppressor genes.

The microsatellite instability pathway results primarily from defects in DNA mismatch repair.

The CpG island methylator phenotype is characterized by widespread promoter methylation and transcriptional silencing of selected genes.

These pathways can overlap, producing substantial molecular heterogeneity among colorectal tumors.

Figure 1. Major Genetic and Epigenetic Events in Colorectal Carcinogenesis

             NORMAL COLORECTAL EPITHELIUM

                       │

                       ▼

              APC / WNT SIGNALING

                 ALTERATION

                       │

                       ▼

                 EARLY ADENOMA

                       │

            ┌──────────┴──────────┐

            ▼                     ▼

       KRAS ACTIVATION       EPIGENETIC

            │                ALTERATIONS

            │                     │

            ▼                     ▼

      CELL PROLIFERATION    DNA METHYLATION

            │              / HISTONE CHANGES

            └──────────┬──────────┘

                       ▼

                 ADVANCED ADENOMA

                       │

             ┌─────────┴─────────┐

             ▼                   ▼

         TP53 LOSS         DNA REPAIR

             │             DEFICIENCY

             │                   │

             ▼                   ▼

       GENOMIC INSTABILITY   MSI / MMR

             │                ALTERATION

             └─────────┬─────────┘

                       ▼

                COLORECTAL CANCER

                       │

                       ▼

             INVASION / METASTASIS

Figure 1: Schematic representation of major genetic and epigenetic events involved in the progression from normal colorectal epithelium to colorectal cancer.

APC and Wnt Signaling

APC is one of the most important tumor-suppressor genes involved in colorectal carcinogenesis.

APC normally participates in regulation of the Wnt–β-catenin signaling pathway.

Loss of APC function can result in accumulation of β-catenin and abnormal activation of Wnt-responsive genes.

This promotes intestinal epithelial proliferation and contributes to early adenoma formation.

APC alterations are frequently considered an initiating molecular event in the conventional colorectal cancer pathway.

KRAS Mutations

KRAS encodes a small GTPase involved in intracellular signaling.

Activating KRAS mutations can lead to persistent signaling through downstream pathways such as RAF–MEK–ERK and PI3K-related signaling.

This promotes proliferation and survival.

KRAS alterations are particularly important clinically because activating mutations can influence the response to therapies targeting the epidermal growth factor receptor pathway.

TP53 Alterations

TP53 encodes a major tumor-suppressor protein involved in DNA damage responses, cell-cycle regulation, senescence, and apoptosis.

Loss or alteration of TP53 function can allow cells containing damaged DNA to continue proliferating.

TP53 alterations are frequently associated with progression from advanced adenoma toward invasive carcinoma.

BRAF Mutations

BRAF is another component of the MAPK signaling pathway.

Activating BRAF mutations can produce persistent downstream signaling and promote cellular proliferation.

BRAF alterations are frequently associated with particular molecular subgroups of colorectal cancer and can overlap with extensive DNA methylation patterns.

PIK3CA and PI3K–AKT Signaling

PIK3CA encodes a catalytic component of phosphatidylinositol 3-kinase.

Alterations in PIK3CA can activate PI3K–AKT signaling and promote cell survival, proliferation, and metabolic adaptation.

Changes in this pathway can cooperate with other genetic abnormalities during colorectal tumor development.

TGF-β Signaling Alterations

Transforming growth factor-β signaling normally contributes to growth inhibition and tissue homeostasis.

Genetic alterations affecting components of this pathway can reduce growth-suppressive signaling.

Genes involved in TGF-β signaling, including SMAD family members, can therefore contribute to colorectal tumor progression when disrupted.

DNA Mismatch Repair

DNA mismatch repair is responsible for correcting errors that arise during DNA replication.

Important mismatch repair proteins include MLH1, MSH2, MSH6, and PMS2.

Loss of mismatch repair function can cause accumulation of mutations, particularly within repetitive DNA sequences known as microsatellites.

This produces microsatellite instability.

Microsatellite Instability

Microsatellite instability is a major molecular characteristic of a subset of colorectal cancers.

Tumors with high microsatellite instability can contain numerous mutations throughout the genome.

MSI may occur because of inherited mismatch-repair defects or acquired epigenetic silencing of mismatch-repair genes.

Microsatellite instability has important diagnostic, prognostic, and therapeutic implications.

Lynch Syndrome

Lynch syndrome is an inherited cancer-predisposition condition associated with defects in DNA mismatch repair.

Individuals carrying pathogenic alterations in mismatch-repair genes have increased risk of colorectal cancer.

The tumors that develop in this setting frequently demonstrate microsatellite instability.

Identification of mismatch-repair deficiency can therefore have implications for both patients and their families.

DNA Methylation

DNA methylation is one of the most extensively studied epigenetic mechanisms in colorectal cancer.

Methyl groups are commonly added to cytosine residues within CpG dinucleotides.

Promoter hypermethylation can reduce transcription of tumor-suppressor genes.

Conversely, global hypomethylation can contribute to genomic instability.

Thus, colorectal cancer can exhibit both localized hypermethylation and widespread genomic hypomethylation.

CpG Island Methylator Phenotype

The CpG island methylator phenotype is characterized by widespread methylation of CpG-rich promoter regions.

This can silence genes involved in cell-cycle control, DNA repair, and tumor suppression.

CIMP-positive tumors frequently display distinct molecular characteristics and can be associated with particular genetic alterations.

The CIMP phenotype therefore represents an important epigenetic route to colorectal carcinogenesis.

MLH1 Promoter Methylation

Epigenetic silencing of the MLH1 gene is an important mechanism of mismatch-repair deficiency in sporadic colorectal cancer.

Promoter hypermethylation can reduce MLH1 expression and impair DNA mismatch repair.

This can result in microsatellite instability and accumulation of mutations.

Histone Modifications

Histones are proteins around which DNA is organized.

Chemical modifications of histones can influence chromatin structure and gene transcription.

Acetylation, methylation, phosphorylation, and other modifications can alter the accessibility of DNA to transcriptional machinery.

Abnormal histone-modifying activity can therefore contribute to colorectal tumor development.

Non-Coding RNAs

Non-coding RNAs are increasingly recognized as important regulators of colorectal cancer biology.

MicroRNAs and long non-coding RNAs can influence gene expression at multiple levels.

They may regulate proliferation, apoptosis, epithelial-to-mesenchymal transition, angiogenesis, invasion, and treatment response.

Changes in non-coding RNA expression can therefore contribute to both tumor initiation and progression.

MicroRNAs in Colorectal Cancer

MicroRNAs are short regulatory RNA molecules that influence expression of multiple target genes.

Several microRNAs have been associated with colorectal cancer.

They can function as oncogenic regulators or tumor suppressors depending on their targets.

For example, dysregulated microRNAs can influence Wnt signaling, apoptosis, cell-cycle regulation, and epithelial-to-mesenchymal transition.

Circulating microRNAs are also being investigated as minimally invasive biomarkers.

Long Non-Coding RNAs

Long non-coding RNAs are transcripts longer than approximately 200 nucleotides that generally do not encode proteins.

They can regulate gene transcription, chromatin structure, RNA stability, and cellular signaling.

Altered long non-coding RNA expression has been associated with colorectal cancer development and metastasis.

Some lncRNAs can interact with microRNAs and influence the expression of cancer-associated genes.

Genetic and Epigenetic Interaction

Genetic and epigenetic alterations do not act independently.

A mutation can alter cellular signaling and subsequently influence epigenetic regulation.

Similarly, epigenetic silencing can suppress DNA repair genes and indirectly increase the accumulation of genetic mutations.

This reciprocal relationship contributes to tumor evolution.

Molecular Heterogeneity of Colorectal Cancer

Colorectal cancer is not a single molecular disease.

Tumors can differ considerably in mutation profiles, DNA methylation patterns, mismatch-repair status, and gene-expression signatures.

This heterogeneity can influence tumor behavior and therapeutic response.

Molecular classification is therefore increasingly important in clinical oncology.

Genetic and Epigenetic Biomarkers

Molecular alterations may serve as diagnostic, prognostic, or predictive biomarkers.

Molecular Alterations and Therapeutic Response

Genetic and epigenetic profiles can influence how colorectal tumors respond to treatment.

KRAS and NRAS mutations, for example, can affect the effectiveness of therapies directed against EGFR signaling.

Mismatch-repair deficiency and high microsatellite instability have important implications for immunotherapeutic strategies.

BRAF alterations can identify tumors with particular molecular characteristics requiring specialized therapeutic approaches.

Epigenetic alterations may also influence treatment response by modifying DNA repair, apoptosis, and cellular differentiation.

Review Design

The present article was prepared as a narrative review focusing on genetic and epigenetic alterations associated with colorectal cancer.

Literature Search

Relevant scientific publications were considered from biomedical databases and peer-reviewed scientific journals.

Search terms included combinations of:

“colorectal cancer,” “genetic alterations,” “epigenetic alterations,” “APC,” “KRAS,” “TP53,” “BRAF,” “microsatellite instability,” “DNA mismatch repair,” “DNA methylation,” “CIMP,” “microRNA,” “long non-coding RNA,” and “colorectal carcinogenesis.”

Inclusion Criteria

Studies were considered relevant when they examined:

• Genetic mutations associated with colorectal cancer;
• DNA mismatch repair;
• Microsatellite instability;
• DNA methylation;
• Histone modifications;
• Non-coding RNAs;
• Molecular classification; or
• Biomarker and therapeutic implications.

Exclusion Criteria

Studies without a substantial focus on colorectal cancer genetics or epigenetics were not emphasized in the synthesis.

Data Synthesis

The available evidence was organized into genetic pathways, epigenetic mechanisms, molecular subtypes, biomarkers, and therapeutic implications.

Results

The reviewed evidence demonstrates that colorectal cancer develops through multiple interacting molecular pathways.

APC alteration and Wnt pathway dysregulation are important early events in the conventional adenoma-carcinoma sequence.

Additional alterations involving KRAS, TP53, BRAF, PIK3CA, and TGF-β-related genes can contribute to tumor progression.

A separate molecular pathway involves mismatch-repair deficiency and microsatellite instability.

Epigenetic mechanisms, particularly promoter DNA methylation and CIMP, represent another major route of colorectal carcinogenesis.

Non-coding RNAs provide an additional layer of gene regulation.

The integration of genetic and epigenetic information has improved molecular classification and provided opportunities for biomarker-guided treatment.

Colorectal carcinogenesis is a complex multistep process driven by the accumulation of molecular abnormalities.

The traditional adenoma-carcinoma sequence provides an important framework for understanding how genetic alterations accumulate during tumor development.

APC dysfunction can initiate abnormal Wnt signaling and promote expansion of proliferating epithelial cells.

Subsequent activation of pathways such as RAS–RAF–MEK–ERK can increase cellular proliferation.

Additional loss of tumor-suppressor functions, including TP53, can facilitate progression toward invasive carcinoma.

However, not all colorectal cancers follow the same molecular sequence.

The microsatellite instability pathway provides a distinct mechanism.

Defective DNA mismatch repair causes accumulation of mutations throughout the genome.

This can generate numerous abnormal proteins that may be recognized by the immune system.

The biological consequences of MSI have contributed to its importance in therapeutic decision-making.

Epigenetic alterations add another level of complexity.

Promoter hypermethylation can silence tumor-suppressor genes and DNA repair genes.

At the same time, global DNA hypomethylation can contribute to chromosomal instability.

The CIMP phenotype illustrates how widespread epigenetic dysregulation can define a molecular subgroup of colorectal cancer.

The interaction between genetic and epigenetic changes is particularly important.

For example, epigenetic silencing of a DNA repair gene can create a mutator phenotype, increasing the probability of additional genetic alterations.

Conversely, oncogenic signaling can influence epigenetic regulators and modify gene-expression programs.

Non-coding RNAs further contribute to this regulatory network.

MicroRNAs can suppress multiple target genes, while long non-coding RNAs can influence chromatin structure and transcription.

Together, these mechanisms create a highly interconnected molecular system.

Clinical Implications

Molecular characterization has become increasingly important in colorectal cancer management.

Testing for mismatch-repair deficiency and microsatellite instability can provide clinically meaningful information.

Analysis of RAS mutations is important when considering EGFR-targeted therapies.

BRAF status can also contribute to molecular classification and therapeutic planning.

Epigenetic biomarkers may eventually complement genetic testing.

The development of liquid biopsy technologies may allow detection of circulating tumor DNA and other molecular signals.

Such approaches could potentially improve detection of residual disease and recurrence.

Future Perspectives

Future research should focus on integrating genetic, epigenetic, transcriptomic, and metabolomic information.

Multi-omics approaches may provide a more complete representation of individual tumors.

Liquid biopsy technologies could also facilitate repeated molecular monitoring without requiring repeated tissue biopsies.

Artificial intelligence and machine-learning approaches may help identify complex combinations of alterations associated with prognosis and treatment response.

Another important direction is the development of epigenetic therapies.

Agents that modify DNA methylation or histone regulation may potentially restore expression of silenced tumor-suppressor genes.

Combination approaches involving genetic-targeted therapies and epigenetic drugs may provide additional therapeutic opportunities.

Genetic and epigenetic alterations are fundamental drivers of colorectal cancer development.

Mutations affecting APC, KRAS, TP53, BRAF, PIK3CA, and DNA mismatch-repair pathways contribute to abnormal proliferation, genomic instability, and tumor progression.

At the epigenetic level, DNA methylation, histone modifications, and dysregulated non-coding RNAs alter gene expression and cellular behavior.

Chromosomal instability, microsatellite instability, and CpG island methylator phenotype represent major molecular routes through which colorectal cancer develops.

The interaction between genetic and epigenetic abnormalities contributes to the substantial heterogeneity observed among colorectal tumors.

Molecular characterization has already improved disease classification and therapeutic selection, particularly through analysis of RAS mutations, BRAF alterations, and mismatch-repair status.

Future integration of multi-omics technologies, liquid biopsy, molecular biomarkers, and precision medicine may further improve early detection, prognostic assessment, and individualized treatment of colorectal cancer.

1. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990;61:759–767.
2. Vogelstein B, Fearon ER, Hamilton SR, et al. Genetic alterations during colorectal-tumor development. New England Journal of Medicine. 1988;319:525–532.
3. Markowitz SD, Bertagnolli MM. Molecular origins of cancer: molecular basis of colorectal cancer. New England Journal of Medicine. 2009;361:2449–2460.
4. Fearon ER. Molecular genetics of colorectal cancer. Annual Review of Pathology. 2011;6:479–507.
5. Gupta AK, Pretlow TP, Schoengold RJ. The pathogenesis of colorectal cancer. Cancer Investigation. 2007;25:526–534.
6. Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012;487:330–337.
7. Guinney J, Dienstmann R, Wang X, et al. The consensus molecular subtypes of colorectal cancer. Nature Medicine. 2015;21:1350–1356.
8. Boland CR, Goel A. Microsatellite instability in colorectal cancer. Gastroenterology. 2010;138:2073–2087.
9. Sinicrope FA, Sargent DJ. Molecular pathways: microsatellite instability in colorectal cancer: prognostic, predictive, and therapeutic implications. Clinical Cancer Research. 2012;18:1506–1512.
10. Issa JP. CpG island methylator phenotype in cancer. Nature Reviews Cancer. 2004;4:988–993.
11. Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB, Issa JP. CpG island methylator phenotype in colorectal cancer. Proceedings of the National Academy of Sciences. 1999;96:8681–8686.
12. Esteller M. Epigenetics in cancer. New England Journal of Medicine. 2008;358:1148–1159.
13. Lao VV, Grady WM. Epigenetics and colorectal cancer. Nature Reviews Gastroenterology & Hepatology. 2011;8:686–700.
14. Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell. 1996;87:159–170.
15. Fearon ER. Molecular genetics of colorectal cancer. Annual Review of Pathology. 2011;6:479–507.
16. Dienstmann R, Vermeulen L, Guinney J, Kopetz S, Tejpar S, Tabernero J. Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer. Nature Reviews Cancer. 2017;17:79–92.
17. Sepulveda AR, Hamilton SR, Allegra CJ, et al. Molecular biomarkers for the evaluation of colorectal cancer. Journal of Clinical Oncology. 2017;35:1455–1463.
18. Cohen JD, Li L, Wang Y, et al. Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science. 2018;359:926–930.
19. Dekker E, Tanis PJ, Vleugels JLA, Kasi PM, Wallace MB. Colorectal cancer. The Lancet. 2019;394:1467–1480.
20. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide. CA: A Cancer Journal for Clinicians. 2021;71:209–249.